Of clinical relevance, high percentage of infiltrating S100A8+ myeloid cells as well as S100A9 expression have been proposed to represent a potential mechanism driving worse prognosis in BC, mostly in TNBC basal-like subtypes [10, 11]. This evidence concerns the gene S100A9 and breast cancer.